Manfred Kaufmann

Q: What Schools Are Affiliated With Manfred Kaufmann

Manfred Kaufmann is affiliated with the following schools: Medical University of Vienna, Otto von Guericke University Magdeburg, MD Anderson Cancer Center, Ludwig Maximilian University of Munich, KU Leuven, University of California, Los Angeles, University of Hamburg, Technical University of Munich

Manfred Kaufmann's AcademicInfluence.com Rankings

Manfred Kaufmann

Philosophy

#7737

World Rank

#10988

Historical Rank

Logic

#4775

World Rank

#6104

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Manfred Kaufmann's Degrees

Doctorate Medicine Stanford University

Why Is Manfred Kaufmann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Manfred Kaufmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. (2012) (1966)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial (2007) (1499)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial (2005) (874)
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. (1998) (834)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. (2006) (671)
From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression (2003) (624)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011) (582)
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. (2009) (532)
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (2000) (527)
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. (2010) (518)
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. (2010) (513)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. (2012) (422)
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer (2012) (412)
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. (2005) (391)
CD44 variant exon epitopes in primary breast cancer and length of survival (1995) (381)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. (2007) (380)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers (2009) (377)
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. (2003) (358)
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. (2002) (334)
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. (2002) (333)
A clinically relevant gene signature in triple negative and basal-like breast cancer (2010) (305)
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer (2008) (301)
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials (2007) (299)
Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. (1996) (296)
Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. (1992) (289)
Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. (1986) (286)
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. (2008) (279)
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. (2007) (260)
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. (2008) (247)
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials (2010) (247)
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. (1997) (245)
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. (2006) (239)
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. (2003) (232)
Response-guided neoadjuvant chemotherapy for breast cancer. (2013) (232)
Treatment of breast cancer during pregnancy: an observational study. (2012) (226)
Locoregional treatment of primary breast cancer (2010) (206)
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells (2004) (200)
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. (2005) (195)
Ceramide synthases and ceramide levels are increased in breast cancer tissue. (2009) (189)
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. (2010) (189)
Identification of high risk breast-cancer patients by gene expression profiling (2002) (179)
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells (2002) (172)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. (2004) (171)
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. (2016) (170)
Comparison of immunohistochemistry and RT‐PCR for detection of CD44v‐expression, a new prognostic factor in human breast cancer (1995) (160)
Breast carcinoma during pregnancy (2006) (159)
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. (2001) (149)
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. (2008) (144)
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. (2003) (137)
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. (2004) (136)
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1 (2002) (134)
P-glycoprotein expression in treated and untreated human breast cancer. (1989) (132)
Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. (1994) (132)
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. (1999) (132)
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy (2007) (131)
Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. (1988) (131)
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. (2013) (127)
Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo (2006) (125)
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast (2008) (124)
Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. (1999) (123)
PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. (2004) (122)
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ (2011) (122)
Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. (2000) (120)
Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. (1979) (120)
Uterotubal transport disorder in adenomyosis and endometriosis—a cause for infertility (2006) (117)
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. (2004) (117)
Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells* (2005) (111)
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy (2009) (111)
Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. (1989) (110)
Use of standard markers and incorporation of molecular markers into breast cancer therapy (2011) (103)
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. (1995) (101)
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol (2008) (99)
Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. (2006) (97)
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. (1994) (94)
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (2005) (93)
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs (2007) (91)
O6‐methylguanine‐DNA methyltransferase activity in breast and brain tumors (1995) (91)
Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer (2009) (89)
Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study (1994) (89)
Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. (2006) (89)
P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial (2005) (85)
Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. (2005) (85)
Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial (2006) (85)
Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures (2011) (85)
Goserelin depot in the treatment of premenopausal advanced breast cancer. (1992) (83)
The role of early expression of inducible nitric oxide synthase in human breast cancer. (2005) (83)
Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer (1999) (83)
Molecular classification of breast cancer patients by gene expression profiling * (2001) (81)
Predictive value of serum interleukin‐6 and ‐8 levels in preterm labor or rupture of the membranes (2000) (80)
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. (2006) (79)
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. (2005) (79)
Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. (1991) (78)
Chemotherapy for metastatic breast cancer-report of a European expert panel. (2002) (78)
Effect of menstrual phase on surgical treatment of breast cancer (1994) (77)
Duration of dysmenorrhoea and extent of adenomyosis visualised by magnetic resonance imaging. (2008) (76)
Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) (2008) (74)
Utero‐Tubal Sperm Transport and Its Impairment in Endometriosis and Adenomyosis (2007) (73)
Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of Plexin B1 (2007) (70)
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. (2005) (69)
Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. (2010) (67)
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. (2010) (67)
Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. (2003) (66)
Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer--results of the analysis of 670 patients with 11 years of follow-up. (2002) (64)
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. (2007) (63)
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC (2005) (63)
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer (2009) (62)
Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages (2000) (61)
Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer (2010) (61)
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. (2012) (60)
Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. (1993) (60)
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. (2007) (59)
Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1 (2005) (59)
Sexual Dysfunction in Breast Cancer Survivors (2004) (59)
Influence of systematic errors on the evaluation of the S phase portions from DNA distributions of solid tumors as shown for 328 breast carcinomas. (1987) (58)
Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue. (1996) (57)
Cytokine release from placental endothelial cells, a process associated with preterm labour in the absence of intrauterine infection. (1999) (57)
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). (2011) (57)
Correlation of dna flow cytometric results and other prognostic factors in primary breast cancer (1988) (56)
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21WAF1/CIP1 (2009) (55)
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. (2010) (54)
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. (2002) (53)
FHL2 Regulates Cell Cycle-Dependent and Doxorubicin-Induced p21Cip1/Waf1 Expression in Breast Cancer Cells (2007) (53)
Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. (2002) (53)
Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. (2011) (53)
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. (1997) (51)
Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters (2004) (51)
Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. (1998) (51)
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. (2002) (50)
Diminished pregnancy rates in endometriosis due to impaired uterotubal transport assessed by hysterosalpingoscintigraphy (2005) (50)
Silencing of mammalian genes by tetracycline-inducible shRNA expression (2007) (50)
S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial. (2011) (49)
DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors (1989) (49)
SATB1 gene expression and breast cancer prognosis. (2011) (48)
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. (2012) (48)
Preoperative (neoadjuvant) systemic treatment of breast cancer. (2005) (48)
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials (2008) (47)
Uterine contractility and directed sperm transport assessed by hysterosalpingoscintigraphy (HSSG) and intrauterine pressure (IUP) measurement (2004) (44)
Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. (1998) (44)
Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study. (2006) (44)
Specific binding of benzodiazepines to human breast cancer cell lines. (1999) (43)
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). (2006) (42)
Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. (1989) (42)
Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. (1996) (41)
Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer (2009) (41)
MIA, a novel serum marker for progression of malignant melanoma. (1999) (40)
Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy (2002) (40)
Anti-fetal immune response mechanisms may be involved in the pathogenesis of placental abruption. (2004) (40)
Abstract S3-1: Lapatinib vs Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44) (2010) (40)
Tumor inhibition by genomically integrated inducible RNAi-cassettes (2006) (39)
Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis. (2009) (39)
Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. (1997) (38)
Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial. (2002) (38)
Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. (1999) (38)
Characterization of WNT7A expression in human endometrium and endometriotic lesions. (2007) (37)
Expression of cytokine receptors in the placenta in term and preterm labour. (1998) (37)
Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer (2008) (37)
Endometriosis may be generated by mimicking the ontogenetic development of the female genital tract. (2007) (36)
Preeclampsia, a pregnancy-specific disease, is associated with fetal monocyte activation. (2001) (36)
DNA flow cytometry of ovarian tumors with correlation to histopathology. (1985) (36)
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. (2010) (35)
Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. (2009) (35)
Expression of ecto-5'-nucleotidase (CD73) in normal mammary gland and in breast carcinoma. (1991) (35)
Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy. (2005) (34)
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. (2000) (34)
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry (2014) (33)
Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast (2004) (33)
Common infections in the history of cancer patients and controls (2005) (33)
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance (2011) (33)
VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection (2009) (32)
Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44 (2004) (32)
Biological impact of freezing Plk1 in its inactive conformation in cancer cells (2010) (32)
Breast carcinoma during pregnancy. International recommendations from an expert meeting. (2006) (31)
Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer (1988) (30)
Phyllodes Tumors of the Breast – Diagnostic and Therapeutic Dilemmas (2007) (30)
Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. (1997) (30)
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy (2005) (30)
Management of breast diseases (2010) (30)
Cell cycle-related expression and ligand binding of peripheral benzodiazepine receptor in human breast cancer cell lines. (2000) (30)
Expression of membrane-type 5 matrix metalloproteinase in human endometrium and endometriosis (2007) (29)
Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer (2013) (29)
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial. (2000) (29)
Evaluation of the Stereotactic 8G Vacuum-Assisted Breast Biopsy in the Histologic Evaluation of Suspicious Mammography Findings (BI-RADS IV) (2005) (29)
Do we need better prognostic factors in nodal-negative breast cancer? Contra. (2000) (28)
Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. (2006) (28)
Differential expression of claudins in human endometrium and endometriosis (2008) (28)
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. (1999) (27)
Effect of humidified and heated CO2 during gynecologic laparoscopic surgery on analgesic requirements and postoperative pain. (2004) (27)
Predictive value of impaired uterine transport function assessed by negative hysterosalpingoscintigraphy (HSSG). (2004) (27)
[Possibilities and limits of pre-therapeutic neoplasm sensitivity cytostatics tests under short-term conditions]. (1975) (27)
Review of known prognostic variables. (1996) (26)
Chemotherapy for ovarian germ cell tumours. (1996) (25)
Clinical relevance of the putative stem cell marker p63 in breast cancer (2010) (25)
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. (2006) (25)
Primary endpoint analysis of the GEPARDUO study: Comparing dose-dense with sequential adriamycin/docetaxel combination as preoperative chemotherapy (PCHT) in operable breast cancer (T2-3, N0-2, M0) (2003) (24)
[Selective tumour chemotherapy using oncobiograms (author's transl)]. (1974) (24)
Comparison of docetaxel/doxorubicin/cyclophosphamide (tac) versus vinorelbine/capecitabine (nx) in patients non-responding to 2 cycles of neoadjuvant Tac chemotherapy - first results of the phase Iii Gepartrio-study by the German Breast Group (2005) (24)
Gemcitabine in ovarian cancer: an overview of safety and efficacy. (1997) (23)
Lamellar body counts in amniotic fluid for prediction of fetal lung maturity (1999) (23)
Value of Electrical Impedance Scanning (EIS) in the Evaluation of BI-RADS™ III/IV/V-Lesions (2005) (21)
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. (2007) (21)
S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab. (2011) (21)
Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System (2010) (21)
The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs (2006) (20)
Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. (1993) (20)
The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group. (1991) (20)
Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients (2005) (19)
Anti‐epidermal growth factor receptor‐antibody therapy for treatment of breast cancer (2002) (19)
Leukocyte adherence inhibition (LAI) tests in patients clinically suspected of having breast cancer using a panel of breast carcinoma extracts. (1979) (18)
Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data. (2010) (18)
Labour-associated expression of intercellular adhesion molecule-1 (ICAM-1) in placental endothelial cells indicates participation of immunological processes in parturition. (1999) (18)
[Development of cancer (vulvar cancer) in the Netherton syndrome (ichthyosis, hair anomalies, atopic diathesis)]. (1987) (18)
Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial. (2004) (18)
Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study (1999) (18)
Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS. (2006) (18)
CD 44 and Metastasis (1994) (17)
A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT) (1998) (17)
Rapid analysis of distinctive CD44 RNA splicing preferences that characterize colonic tumors. (1997) (17)
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. (2008) (17)
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group. (2005) (16)
Silencing of the HER 2 / neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER 2 / neu – Overexpressing Breast Cancer Cells 1 (2014) (16)
Combination of new biologic parameters as a prognostic index in epithelial ovarian carcinoma (1995) (16)
56. Long-term follow-up of breast cancer patients with micrometastatic tumour cells in bone marrow at primary surgery — prognostic impact in comparison to nodal status (1995) (16)
Surgical procedure can explain varying influence of menstrual cycle on prognosis of premenopausal breast cancer patients (1995) (16)
Do we need better prognostic factors in node-negative breast cancer? Pro, Contra and arbiter (2000) (16)
Umbilical endometriosis in pregnancy without previous surgery. (2008) (16)
Comparison of neoadjuvant 6 vs 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study. (2006) (16)
Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. (2009) (15)
Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study (2004) (15)
Aromatase inhibitors: a safety comparison (2007) (14)
Spontaneous apoptosis in ovarian cancer: an unfavorable prognostic factor. (1998) (14)
A review of endocrine options for the treatment of advanced breast cancer. (1997) (14)
Angiogenesis as a Diagnostic Factor in Primary Breast Cancer: Microvessel Quantitation by Stereological Methods and Correlation with Color Doppler Sonography (1994) (14)
Abstract S6-2: 313 Patients with Breast Cancer during Pregnancy — Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03) (2010) (14)
Sensitivity tests of tumors to cytostatic agents (2004) (13)
The value of bone marrow examination for tumor staging in breast cancer (1988) (13)
Ovarian Cancer Antigen CA 125 Enhances the Invasiveness of the Endometriotic Cell Line EEC 145 (1999) (13)
Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades (2013) (13)
Use of goserelin in the treatment of breast cancer (2005) (13)
[Current state of chemosensitivity testing of tumors]. (2008) (13)
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) (2011) (12)
Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas (1996) (12)
Psammomabody content and DNA-flow cytometric results as prognostic factors in advanced ovarian carcinoma. (1988) (12)
Breast cancer during pregnancy--A prospective and retrospective European registry (GBG-20/BIG02-03) (2008) (12)
Prognostic importance of DNA-ploidy and S-phase fraction in endometrial cancer (1993) (12)
Monoclonal antibodies to detect breast cancer cells in bone marrow. (1994) (12)
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long? (2006) (11)
Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. (2005) (11)
Demographic and psychosocial factors associated with risk perception for breast cancer. (2005) (11)
Pregnancy after the calcium ionophore correction of pronuclei position in oocytes after intracytoplasmic sperm injection. (2010) (11)
The cellular mechanisms involved in leucocyte adherence inhibition (LAI) tests of patients with breast cancer (1981) (10)
DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases (2005) (10)
[Therapy of ascites with tumor necrosis factor in ovarian cancer]. (1990) (10)
Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer. (1986) (10)
Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer. (2008) (10)
Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial. (2007) (10)
New endocrine approaches in the treatment of breast cancer. (1998) (10)
DNA Flow Cytometry of Ovarian Tumors with Correlation to Histopathology (1985) (10)
in vivo chemosensitivity-adapted neoadjuvant chemotherapy (docetaxel-doxorubicin-cyclophosphamide followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: results of the Gepar- trio randomized pilot study (2003) (10)
[Cervical cancer screening of HIV-positive women: is a prolongation of the screening interval meaningful?]. (2006) (10)
Prospective evaluation of the leukocyte adherence inhibition (lai) test in breast cancer using a panel of extracts from known and unknown primary tumors (1982) (10)
[Diagnosis of benign and malignant ovarian tumors]. (1985) (10)
Sensitivity tests of tumors to cytostatic agents (2004) (10)
Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin® (exemestane), in advanced breast cancer patients having progressed on antiestrogens (1999) (9)
Androgen Receptor Expression in Ductal Carcinoma In Situ of the Breast: Not a Helpful Marker for Classification Such as Estrogen Receptor α and Progesterone Receptor (2005) (9)
Zoladex in the treatment of premenopausal metastatic breast cancer patients. (1989) (9)
Identification and functional characterization of the human and murine fibroblast growth factor receptor 4 promoters. (2000) (9)
[The role of stereotactic 11G vacuum biopsy for clarification of BI-RADS IV findings in mammography]. (2003) (8)
S4-7: Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. (2011) (8)
[Anesthetic regimen for HIV positive parturients undergoing elective cesarean section]. (2003) (8)
Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. (2012) (8)
[Fetal damage due to mushroom poisoning with amanita phalloides during the first trimester of pregnancy (author's transl)]. (1978) (8)
[Isolated decrease of haptoglobin during pregnancy: diagnosis by chance or pathological? ]. (2002) (8)
Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials. (2010) (8)
Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1). (1989) (8)
P107 The ‘ZEBRA’ study: ‘Zoladex’ (goserelin) vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less (1998) (8)
[Reproduction after breast cancer: what advice do we have for our patients?]. (2005) (8)
Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1). (1989) (8)
The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer (2011) (7)
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]. (2001) (7)
Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials. (1998) (7)
Metastatic Bone Disease (1994) (7)
The emerging role of hormonal ablation as adjuvant therapy in node + and node – pre-/perimenopausal patients (2001) (7)
Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam). (2014) (7)
Cervical intraepithelial neoplasia in human immunodeficiency virus-positive patients. (2000) (7)
Controversies Concerning the Use of Neoadjuvant Systemic Therapy for Primary Breast Cancer (2012) (6)
c-kit: Identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features. (2006) (6)
499 Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03) (2008) (6)
"Stem cell like" breast cancers-a model for the identification of new prognostic/predictive markers in endocrine responsive breast cancer exemplified by Plexin B1. (2008) (6)
Toremifene: Clinical Phase II/III Trials of a New Antiestrogen in Patients with Advanced Breast Cancer (1989) (6)
[Clinical course of ovarian cancer in relation to morphologic prognostic factors and cell kinetic parameters]. (1987) (6)
Clinical correlates of in vitro effect of adriamycin on advanced lung carcinoma (1976) (6)
[The positive "vocal fremitus" in malignant breast tumors in color MEM ultrasound imaging--an exciting artifact in confirming the diagnosis?]. (1994) (6)
Repeated Ectopic Pregnancy After ICSI Therapy and Embro Transfer - A Case Report and Literature Review (2006) (6)
313 Patients with breast cancer during pregnancy – a prospective and retrospective registry (GBG-20 / BIG02-03) (2010) (6)
Imaging , Diagnosis , Prognosis A New Molecular Predictor of Distant Recurrence in ER-Positive , HER 2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011) (6)
[Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III)]. (2006) (6)
[Uterine adenomyosis in infertile patients: MR imaging findings and clinical conclusions]. (2004) (6)
[Hysteroscopic endometrium ablation in "high-risk" situations and in hemorrhagic diathesis]. (1995) (6)
P2-12-26: Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer – Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease. (2011) (6)
Adjuvant hormone therapy following primary therapy for endometrial cancer. (2002) (6)
In vitro evaluation of an estradiol-linked nitrosourea in mammary carcinomas of mouse, rat and man. (1988) (6)
Antitumor effect of MAb EMD 55900 depends on EGF-R expression and histopathology. (2002) (6)
Extended and Continuous Use of Hormonal Contraceptives to Reduce Menstruation (2006) (6)
[Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma]. (1996) (6)
A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy. (2011) (6)
EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy (2003) (6)
Eff ectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer : a meta-analysis (2006) (5)
Pegfilgrastim alone or with ciproflaxin significantly reduces febrile neutropenia and hospitalization vs G-CSF alone in breast cancer patients receiving neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) (2006) (5)
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer) (2009) (5)
LEUCOCYTE-ADHERENCE-INHIBITION TEST IN BREAST CANCER (1978) (5)
[Adjuvant chemo-hormonal therapy of breast cancer. New results on mortality]. (2008) (5)
Utero-tubal transport disorder in adenomyosis and endometriosis—a cause for infertility (2006) (5)
TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial. (2004) (5)
Selective inhibition of leukocyte adherence in women with breast cancer using a variety of tissue extracts. (1978) (5)
[Ultrasound diagnosis of blood flow in benign and malignant breast tumors]. (1992) (5)
[Incontinence operation by "Retzius-scopy"? An endoscopic modification of the Marshall-Marchetti-Krantz operation]. (1994) (5)
Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer (2010) (5)
In-vitro testing of cyclophosphamide on tumors (1975) (4)
PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy. (2011) (4)
[Intercellular adhesion molecular 1, a diagnostic serum marker in chorioamnionitis, pre-eclampsia and HELLP syndrome]. (2000) (4)
Breast Cancer Proteomics – Differences in Protein Expression between Estrogen Receptor-Positive and -Negative Tumors Identified by Tandem Mass Tag Technology (2010) (4)
[Sensitivity testing of malignant human tumors against cytostatic agents. II]. (1972) (4)
[The prognostic significance of tumor cell detection in bone marrow of patients with breast cancer]. (1990) (4)
[Effect of a new beta-receptor blockader (LB 46, Visken) on systemic and pulmonary hemodynamics and on coronary blood flow in humans]. (1971) (4)
[Integrin expression in eutopic and ectopic endometrium]. (2006) (4)
Adjuvant Treatment with Trastuzumab in Patients with Breast Cancer (2006) (4)
Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer. (2006) (4)
369 Advanced breast cancer: A phase II trial with gemcitabine (GEM) (1995) (4)
Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: A randomized study comparing different times and routes of administration of corynebacterium parvum (1984) (4)
Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93. (2004) (4)
[Qualification and education in gynecological oncology]. (2006) (4)
Organübergreifendes Debulking in Kombination mit intraoperativer Strahlentherapie (IORT) im multimodalen Therapiespektrum von Beckenrezidiven (1998) (4)
[Extent of psammoma carcinomas of the ovary--a clinical, DNA flow cytophotometric and morphometric image analysis study]. (1990) (4)
A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide) (2004) (4)
Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup Study. (2010) (4)
[Short-term incubation in vitro with precursors of nucleic acids on human primary tumors and metastases of carcinoma of the breast (author's transl)]. (1978) (4)
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. (2010) (4)
Is the sonographic degree of blood supply a new prognostic factor (1996) (4)
Allelic imbalance in three distinct regions on chromosome 17q in sporadic breast cancer correlates with prognostic parameters (1997) (4)
Conventional Clinical Risk Factors HER 2-Negative Breast Cancer Adds Independent Information to A New Molecular Predictor of Distant Recurrence in ER-Positive (2011) (4)
Cancer of the uterine cervix is susceptible to anti-EGF-R antibody EMD 55,900 therapy. (2005) (4)
[PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients]. (2006) (4)
Darbepoetin alfa as primary prophylaxis of anemia in patients with breast cancer treated preoperatively with docetaxel/doxorubicin/cyclophosphamide. (2006) (3)
Impaired utero-tubal sperm transport in adenomyosis and endometriosis—a cause for infertility (2004) (3)
Detection and Characterization of Tumor Cells in Bone Marrow of Patients with Primary Breast Cancer (1994) (3)
Current and New Concepts in the Systemic Adjuvant Treatment of Breast Cancer (1993) (3)
[Disturbed utero-tubal transport in hysterosalpingoscintigraphy as a predictive functional test for IVF therapy]. (2002) (3)
Immuncompetent cells and endothelial cells are the sources of elevated placental cytokine production in term and preterm labor (1997) (3)
Metabolism of debrisoquine and susceptibility to breast cancer (1991) (3)
Ifosfamide combination chemotherapy in advanced breast cancer (2004) (3)
Adjuvant Chemo-Endocrine Therapy (1994) (3)
Adjuvant chemotherapy with chlorambucil and 5-fluorouracil in primary breast cancer (Cooperative Study Heidelberg). (1980) (3)
5002 MoniCa: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer (GBG39) (2009) (3)
Psychotherapy in support of patients undergoing antineoplastic chemotherapy. (1988) (3)
[Chemoprevention of breast cancer: a literature review and report on the current status in Germany]. (2003) (3)
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? (2001) (3)
[Adjuvant (preventive) postoperative chemotherapy in breast carcinoma]. (1978) (3)
64. Tamoxifen does not promote tumour progression in surgically treated endometrial cancer (1995) (3)
[Case report -- needle in the breast]. (2006) (3)
Detection of Breast Cancer Cells in Bone Marrow1 (1995) (3)
Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer (2004) (3)
Human breast tumors containing non-DNA-binding immunoreactive (67 kDa) estrogen receptor (2004) (3)
A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by corynebacterium parvum in metastatic breast cancer (1982) (3)
E10. Breast cancer during pregnancy (2004) (3)
Combination of Grading and New Biological Factors (S-Phase Fraction and Epidermal Growth Factor Receptor) Can Predict Relapse and Survival in Patients with Node-Negative Primary Breast Cancer (1994) (3)
Brusterhaltende Operation und adjuvante Therapie beim Mammakarzinom Bericht über die National Institute of Healths (NIH) - Consensus Development Conference Washington D. C., 18. - 21. Juni 1990 (1990) (2)
Mitoxantrone plus docetaxel vs single agent mitoxantrone in metastatic breast cancer (MBC): Results of a multicenter randomized trial. (2004) (2)
Relevance of CD44 Variant Epitopes for Diagnosis and Therapy of Human Breast Cancer (1995) (2)
Phase I study of ZEN-008 (AN-152), a targeted cytotoxic LHRH analog, in female patients with cancers expressing LHRH receptors. (2006) (2)
492 Safety and efficacy of taxol® (paclitaxel) over 3 h in 306 platinum-refractory patients with ovarian cancer: Results of a German cooperative study (1995) (2)
Randomised trial comparing zoladex∗ with nolvadex∗ plus zoladex in pre-menopausal advanced breast cancer (1992) (2)
CD44 variant exon epitopes and primary breast cancer (1995) (2)
[Heterologous and autologous breast reconstruction--current status. Report on the 2d Congress of the Society of Reconstructive Surgery in Gynecology 22 to 24 February 1991 in Baden-Baden]. (1991) (2)
Effectiveness of Vinorelbine/Capecitabine (NX) versus Docetaxel/Doxorubicin/Cyclophosphamide (TAC) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy: First Results of the phase III GEPARTRIO-Study by the German Breast Group (2006) (2)
AGO Recommendations for the Diagnosis and Therapy of Breast Cancer (2007) (2)
Mitoxantrone (N) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first line therapy in high-risk metastatic breast cancer (1997) (2)
Clinical Outcome after Myomectomy versus Uterine Artery Embolization for Uterine Fibroids (2007) (2)
[Hysteroscopic endometrium ablation to avoid hysterectomy in "high risk" patients]. (1994) (2)
[Prognostic significance of cell kinetic parameters of endometrial cancer]. (1989) (2)
An eight weeks dose-dense versus a 24 weeks sequential adriamcycin/docetaxel combination as preoperative chemotherapy (CHT) in operable breast cancer (T2-3, N0-2,M0) (2001) (2)
Cyclins and Breast Cancer (1998) (2)
First-Line Monochemotherapy with Mitoxantroneversus Combination with Fluorouracil, Epirubicin and Cyclophosphamide in High-Risk Metastatic Breast Cancer: A Prospective Randomized Multicenter Clinical Trial (2000) (2)
Prognostic Factors in Primary Breast Cancer (1989) (2)
[Feather--data acquisition in gynaecology and obstetrics]. (2002) (2)
Expression and function of the four and a half LIM-only protein 2 (FHL2) in breast cancer (2006) (2)
[Morphologic criteria of prognosis and clinical course in ovarian tumors of the borderline type]. (1987) (2)
Interdisciplinary Consensus on the Use of Adjuvant Bisphosphonate Therapy in Breast Cancer Patients (2009) (2)
Mitomycin-C, 5-FU, Folinic Acid (Mi-Fu-Fo) as salvage chemotherapy for hepatic failure due to liver metastases in breast cancer (2004) (2)
Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (2006) (2)
Updated survival results from the Zebra trial. (2002) (2)
Prognostic relationship of SATB1 gene expression and estrogen receptor status in breast cancer cells. (2010) (2)
371 In vivo-chemosensitivity adapted primary chemotherapy in patients with primary breast cancer. First results of the Gepartrio-Pilot trial (2003) (2)
A methodologically improved definition of chemosensitivity indices. (1982) (2)
11th International Conference St. Gallen: Primary Therapy of Early Breast Cancer (2009) (2)
Adjuvant Systemic Therapy in Node-Negative Breast Cancer (1990) (2)
[Side effects and complications in breast-saving therapy of breast cancer]. (1989) (2)
Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. (2012) (2)
[Zoladex as a depot GnRH agonist in premenopausal metastatic breast cancer]. (1989) (2)
[The second-look operation in advanced ovarian cancer--experiences since the introduction of cisplatin combination chemotherapy]. (1986) (2)
Mepivacaine for spinal anesthesia in parturients undergoing elective cesarean delivery: maternal and neonatal plasma concentrations and neonatal outcome. (2003) (2)
Methodical Bias of Retrospective Follow-up Investigations and Impact on the Collection of Quality Assurance Data (2010) (2)
[Carcinomatous meningeosis during cis-platinum treatment of gynaecological cancers (author's transl)]. (1982) (2)
[Diagnosis of tubal function using intraluminal ultrasound--initial results]. (1992) (2)
Validated 3 Gene Signature Predicts Response to Neo-Adjuvant Chemotherapy in Luminal Breast Cancer – Results from GeparTrio and GeparQuattro. (2009) (2)
[Identification of preeclampsia by cDNA-gene expression profiling in human placentas and serum -- a pilot study]. (2006) (2)
[The effect of cyclophosphamide on tumors in the sensitivity-test (author's transl)]. (1975) (2)
P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2−Negative Breast Cancer. (2011) (2)
Prevention Trials in Women at Moderate Risk of Breast Cancer (2006) (1)
[Giant cell sarcoma: a rare breast tumor]. (1989) (1)
Clinically relevant gene signatures in triple-negative and basal-like breast cancer. (2010) (1)
[Clinical observations in connection with an endemic accumulation of Echo-9 infections]. (1967) (1)
Attitude towards the prevention of breast cancer — results of a survey of women with an average risk of breast cancer (n=7000) and free-practising gynaecologists (n=800) in Germany (2004) (1)
POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE EARLY BREAST CANCER TREATED ON THE TEAM TRIAL OF ADJUVANT ENDOCRINE THERAPY (2010) (1)
[Management of abnormal uterine bleeding]. (2006) (1)
Lapatinib Can Be Safely Given Concomitantly to EC-Doc as Neoadjuvant Chemotherapy for Breast Cancer. First Planned Safety Analysis of the Geparquinto Study (GBG 44). (2009) (1)
[Three-dimensional ultrasound imaging of benign and malignant breast tumors--initial clinical experiences]. (1992) (1)
Brusterhaltende Operation und adjuvante Therapie beim Mammakarzinom (1990) (1)
Influence of surgical trauma on tumor establishment in a rat ovarian cancer model (2004) (1)
Laser palliation of locoregional recurrences of breast cancer. (1991) (1)
Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. (2011) (1)
[New aspects in diagnosis and therapy of endometriosis]. (2004) (1)
Effect of menstrual phase on surgical treatment of breast cancer. (1994) (1)
The Blood Circulation of Malignant and Benign Tumours of the Genital Interior as a Diagnostic Tool (1994) (1)
[Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer]. (1988) (1)
Workshop ‘Psychoneuroimmunology in Relation to Cancer’ vom 3.-7. Juni 1990 in Tutzing (1990) (1)
[Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006]. (2006) (1)
[Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)]. (1979) (1)
Residual cancer burden in locally advanced breast cancer: a superior tool (2009) (1)
[Histochemical and electron microscopical studies in capsule fibroses following prosthetic augmentation of the breast]. (1979) (1)
Laparoskopische Operationen in der Gynäkologie (2006) (1)
[Adjuvant therapy in Operable non-small cell lung cancer]. (1983) (1)
Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only (1993) (1)
Toxicity-adapted dosing of topotecan in non-taxane-pre-treated, recurrent ovarian cancinoma (2001) (1)
[Systemic therapy of operable carcinoma of the breast]. (2005) (1)
Hysteroscopic septal resection, the treatment of choice in patients with subseptate uterus: postoperative pregnancy rates (2002) (1)
The GISS Trial: A pilot phase randomized prevention trial of screening plus goserelin plus ibandronate, versus screening alone in premenopausal women at high risk of breast cancer (2008) (1)
Does Sphingosine Kinase 1 (SPHK1) Play a Role in Endometriosis (2009) (1)
[B-streptococci in obstetrics--risks and consequences of maternal colonization and neonatal contamination]. (1992) (1)
[Endoscopic colposuspension ("retziusscopy" versus laparoscopy). An effective extension of the surgical spectrum of stress incontinence?]. (1995) (1)
P3-01-12: Prognostic Impact of RANK, RANKL and OPG Gene Expression in ER Positive Primary Breast Cancer. (2011) (1)
[CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer]. (1988) (1)
8. Prophylaxis and treatment of side-effects (1989) (1)
Current Trials of the German Adjuvant Breast Cancer Group (GABG) (1998) (1)
[Preoperative chemotherapy of breast carcinoma]. (1998) (1)
[Effect of surgical procedure and adjuvant therapy on cosmetic results after breast conserving therapy in breast cancer]. (1991) (1)
Prognostic Value of Gene Signatures and Tumorbiological Characteristics in Breast Cancer Patients Treated with Anthracycline-containing Chemotherapy (2008) (1)
What do adjuvant and metastatic breast cancer patients (BC) expect from their doctors? Final results of a german survey in 617 patients. (2006) (1)
CD44 isoforms in prognosis of breast cancer (1995) (1)
Prospective randomized studies are needed to define the role of axillary lymph node dissection in primary breast cancer. (1997) (1)
Disseminated tumor cells in the bone marrow of ductal carcinoma in situ patients. (2011) (1)
Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes. (2010) (1)
Intrapleurale (i.pl.) Applikation von rekombinantem humanem Tumornekrosefaktor α (rHu TNF) bei malignen Pleuraergüssen (1991) (1)
[Genetic diagnosis and therapy of hereditary breast carcinoma]. (1995) (1)
[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]. (2006) (1)
P44 First experience with gosereline and ibandronate as medical prevention in premenopausal patients with increased familiary breast cancer risk: The GISS study (2004) (1)
Internet expert system on breast cancer — Two years experience with a German web site (www.mammakarzinom.de) (1999) (1)
[Lymphangiosis carcinomatosa of the skin in ovarian cancer simulating scleroderma]. (1991) (1)
Guidelines – Inflation or Help in Clinical Routine? (2008) (1)
[Breastfeeding nursing after breast surgery]. (2002) (1)
[Uterine rupture after uterine perforation during D & C and diagnostic hysteroscopy in a patient with endometrial polyp]. (2003) (1)
Expression and function of the four and a half LIM-only protein 2 (FHL2) in breast cancer. (2005) (1)
[New aspects by the therapy of ovarian cancer--What changes after the ASCO-Meeting 2001]. (2002) (1)
Geparquinto: An interim safety analysis of epirubicin/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy for primary breast cancer patients. (2016) (1)
Expression and prognostic role of angiogenic and cell-cycle markers in serous ovarian carcinomas. (2007) (0)
Kongressbericht der 45. Jahrestagung der American Society of Clinical Oncology, Orlando 29.5.–2.6.2009 (2009) (0)
Clinical observations during an endemic of echovirus 9. (1967) (0)
Breast-Conserving Therapy or Amputation with Reconstruction: The Patient’s View (1989) (0)
Late abstracts 186–187 (2005) (0)
Prognostic relevance of alterations in sphingolipid metabolism in breast cancer (2008) (0)
[Management of HIV-positive pregnancies -- results from a retrospective study]. (2005) (0)
[Testing the resistance of human tumor and bone marrow cells to cytostatic agents]. (1978) (0)
Cytokeratin antibodies in the early detection of bone marrow involvement in breast cancer (1986) (0)
Abstract P3-14-19: Long-Time Tumor Remissions under Trastuzumab Therapy in HER2- Positive Locally Recurrent or Metastatic Breast Cancer: First Interim Analysis of the HER-OS Database (2010) (0)
[Morphological and clinical aspects of the so-called sinus tumours of the ovary (author's transl)]. (1981) (0)
[Therapeutic strategy in advanced breast carcinoma]. (1998) (0)
134O RESULTS OF FDG-PET/CT AFTER FIRST CYCLE OF NEOADJUVANT CHEMOTHERAPY REFLECT TUMOR CHARACTERISTICS IN BREAST CANCER: POSSIBLE VALUE OF SUV CHANGES DURING CHEMOTHERAPY IN PREDICTION OF TUMOR BIOLOGY AND CHARACTER (2008) (0)
[Rate of local recurrence and survival in patients with breast reconstruction following mastectomy]. (1988) (0)
Progressive ulceration and wound healing complication secondary to bevacizumab in a patient with metastatic breast cancer (2008) (0)
[Reconstruction following ablatio]. (1979) (0)
Tamoxifen and its gynaecological consequences (2000) (0)
Estrogen receptors in bone marrow biopsies of breast cancer metastatic to the skeletion (1986) (0)
[Breast saving operation and adjuvant therapy of breast cancer. Report of the National Institute of Health (NIH) consensus development conference, Washington, D.C., USA, 18-21 June 1990]. (1990) (0)
11. Dosismodifikationen, maximale Gesamtdosen (1989) (0)
[Sentinel lymph node biopsy in breast cancer]. (2004) (0)
Predictive and Prognostic Markers in Breast Cancer Treatment – Presentations at the 28th San Antonio Breast Cancer Symposium 2005 (2006) (0)
c-kit: identification of coregulated genes in breast cancer patients by gene expression analysis (2006) (0)
Operable Breast Cancer: Neoadjuvant Treatment (Methodology) (2008) (0)
How reliable are conventional and color-coded sonography of the breast in the differential diagnosis of breast cancer? (1996) (0)
Kongressbericht vom 31. Annual San Antonio Breast Cancer Symposium von 10.–14.12.2008 (2009) (0)
[New strategies for therapy of breast cancer. San Antonio Breast Cancer Symposium, 2002]. (2002) (0)
Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer. (2009) (0)
0048 Prognostic value of gene expression of ASAH1, LASS4 and LASS6 in breast cancer (2009) (0)
10. Follow-up examinations (1989) (0)
PD03-02: Prognostic and Predictive Predictors for Triple Negative Breast Cancer. (2011) (0)
Anastrozole (Arimidex) Realising the Need for an Oral Selective Aromatase Inhibitor: Satellite Symposium held at the 21st Congress of the European Society for Medical Oncology, Vienna, October 1996 (1997) (0)
669 A phase III randomized trial of bendamustinehydrochloride, methotrexate, and 5-FU (BMF) versus CMF as first-line treatment of patients with metastatic breast cancer (2003) (0)
Micrometastatic tumor cells in bone marrow versus nodal status in breast cancer—Impact on prognosis in patients with primary breast cancer (2007) (0)
[Primary combined chemotherapy following removal of an endodermal sinus tumor or yolk-sac tumor of the ovary (author's transl)]. (1976) (0)
[Malignant disease in pregnancy: the interdisciplinary management from the gynecologist's point of view]. (2009) (0)
[Immunodiagnostic aspects of breast cancer (author's transl)]. (1978) (0)
The congruity between urine and cervical swab cultures in pregnant women with versus without amniotic fluid infection. (2005) (0)
4. Chemotherapy General outlines (1989) (0)
New transobturator sling for less invasive treatment of urinary incontinence in women--SERASIS TO. (2005) (0)
[New methods for treating surgically incomplete or inoperable recurrences of gynecologic malignancies]. (1991) (0)
TARGIT-A trial: Updated results for local recurrence and survival for the German centers. (2013) (0)
Lapatinib in HER2+ early breast cancer: Quality of life analysis. (2012) (0)
[Sensitivity testing of chemotherapeutic agents for ovarian and breast cancers--possibilities and limits of different methods and of their application (author's transl)]. (1982) (0)
[Compliance in adjuvant chemotherapy]. (1986) (0)
[Fractionated diagnostic aspiration curettage (proceedings)]. (1977) (0)
International E xpert P anel o n t he U se o f P rimary (Preoperative) S ystemic T reatment o f O perable B reast C ancer: Review a nd R ecommendations (2003) (0)
13. After-care (1989) (0)
[Management of breast cancer treatment -- a multidisciplinary approach]. (2004) (0)
[Proceedings: Pretherapeutic sensitivity testing for chemotherapy of tumors]. (1974) (0)
Internat ional Expert Panel on the Use of Pr imary ( Preoperat i ve ) Systemic Treatment of Operable Breast Cancer : Rev iew and Recommendat ions (2003) (0)
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry (2014) (0)
12. Evaluation of therapy results and documentation (1989) (0)
Updates from the TARGIT A trial for the German centers: Local recurrence and survival (2014) (0)
O-3 Long-term results from the ZEBRA trial comparing Goserelin with CMF as adjuvant therapy in premenopausal women (2007) (0)
[Systemic therapy in recurrent and primary advanced cervix cancer]. (1991) (0)
[Adjuvant therapy of breast carcinoma]. (1994) (0)
5050 Capecitabine provides substantial quality of life gain in patients with pretreated metastatic breast cancer (2009) (0)
6. Objectives of chemotherapy (1989) (0)
P96 Randomized trials to assess the effectivity of tamoxifen as adjuvant treatment in node-negative and receptor positive breast cancer. The Heidelberg II and GABG II trials (1998) (0)
Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial (2012) (0)
Wilke H, et al.: Phase II study with folinic acid, etoposide, 5-fluorouracil and cisplatin (FLEP) for advanced gastric cancer. Onkologie 1994;17:154-157 (this issue) (1994) (0)
Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer. (2009) (0)
[A case from practice (194). Relapsing fever]. (1990) (0)
[General management and operative therapy of progressive or recurrent ovarian cancer]. (1985) (0)
[Clinical aspects and morphology of extra-ovarian serous cancer of the pelvis]. (1990) (0)
[DNA measurement of malignant tumors by impulse cytophotometry. The principles and importance for assessing growth behavior and the degree of abnormality]. (1984) (0)
[Etiology, clinical aspects and therapy of dissecting aortic aneurysm]. (1971) (0)
Adjuvant hormonotherapy (Tamoxifen versus medro-xyprogesterone acetate versus control) in women with endometrial cancer, figo stage I and II (1986) (0)
[Report on the NIH Consensus Development Conference on Adjuvant Therapy of Breast Carcinoma]. (2001) (0)
Laser in Gynecologic Oncology? Laser Palliation of Malignoma Recurrences (1992) (0)
[Therapy in metastasizing ovarian cancer--survival rate correlated with histological and cytological grading as prognostic factors]. (1983) (0)
Gene expression of topoisomerase II alpha by microarray analysis is highly prognostic in estrogen receptor (ER)+ breast cancer – prognostic value of Topoisomerase II alpha (2008) (0)
Allelic imbalances on chromosome 17 are associated with aneuploidy and steroid hormone receptor negativity in sporadic breast cancer (2007) (0)
[In-vitro resistance testing of human ovarian carcinomas--short-term test for the demonstration of proliferation-kinetic and biochemical resistances]. (1978) (0)
[After care, rehabilitative and social measures in genital and breast neoplasms]. (1979) (0)
478 Efficacy of first-line capecitabine 1,000 mg/m2 b.i.d. in patients with metastatic breast cancer (MBC) (2010) (0)
Hormone-dependent tumors ; basic research and clinical studies (1995) (0)
[Value of steroid hormone receptors as prognostic factors in breast, ovarian and endometrial cancer]. (1993) (0)
P2-12-11: Clinical Relevance of a IL-8/B-Cell Gene Signature Identified from Triple Negative Breast Cancer (TNBC) in Intrinsic Breast Cancer Subtypes. (2011) (0)
The role of chemical castration in the treatment of breast cancer in 1993 (1994) (0)
[Demonstration of cellular immunity by means of the leukocyte adherence inhibition (LAI) test in female breast neoplasms]. (1978) (0)
[Clinical management of an androgen insensitivity syndrome]. (2006) (0)
3. General aspects of antineoplastic chemotherapy (1989) (0)
[Dental-stomatological problems before, during and after tumor radiotherapy i n the head and neck region]. (1978) (0)
[Paraneoplastic cerebellar degeneration: case report of a patient with breast carcinoma]. (1996) (0)
[Determination of coronary circulation with 131 -iodine antipyrine]. (1971) (0)
[New aspects of carcinoma of the breast therapy and of gynaecological carcinoma treatment]. (2003) (0)
[Cardiovascular problems in adolescence]. (1970) (0)
Abstract P2-10-17: SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study. (2012) (0)
Title Page / Contents / Preface to the 1st edition / Preface to the 2nd edition / Preface to the 3rd edition / Preface to the 4th Edition (1989) (0)
Inkontinenz-OPs mit Meshes, TVT/TOT (2006) (0)
Understanding the data, meeting patients' needs. (2008) (0)
Leukemia - Inhibitory Function of T / Cells in patients with AML (1991) (0)
[Breast reconstruction using a skin expander prostheses following modified radical mastectomy]. (1988) (0)
[Amniotic fluid embolism as an obstetric emergency--description of the syndrome and a case with fatal outcome]. (2001) (0)
Mitoxantrone and prednimustine combination chemotherapy in breast cancer. (1989) (0)
[Immunocytochemical estrogen receptor determination in metastatic breast cancer]. (1989) (0)
Tandem mass technology: A helpful tool for proteomic research in breast cancer? (2010) (0)
Advanced Breast Cancer (2002) (0)
CD44 splice variants in tumor metastasis (1993) (0)
Meetings and Conferences · Tagungen und Kongresse (2012) (0)
[In vitro study of estradiol-linked nitrosourea in breast cancers in the mouse, rat and human: interspecies comparison]. (1989) (0)
7. Therapy for tumors of the female genital organs and the breast (1989) (0)
The Luminal B Marker NHERF1 Predicts Endocrine Resistance. (2009) (0)
Selecting patients for chemotherapy on the basis of tumour characteristics (1995) (0)
[San Antonio Breast Cancer Symposium -- highlights 2004]. (2005) (0)
P42 Prevention of breast cancer: Results of a survey towards attitudes of women with an average risk of breast cancer (n = 7000) and gynaecologists (n = 800) in Germany (2004) (0)
[Testing of the resistance of human tumours in the short-term test (author's transl)]. (1975) (0)
Prospective randomized study of bromoergocryptin (B) in patients with metastatic breast cancer: Results from the X/82 multicenter trial (1986) (0)
Letrozole improves survival compared with megestrol acetate among women with advanced breast cancer (2002) (0)
Adjuvant Consensus: A Breast Cancer Patient Web Tool (2008) (0)
Current trials of the German Adjuvant Breast Cancer Group (GABG). (1998) (0)
Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC). (2011) (0)
BRCA1 and BRCA2 mutations in Germany - indications for testing in hereditary breast and ovarian cancer families. (2004) (0)
Use of TNF and LT in the manufacture of pharmaceutical products. (1989) (0)
Abstract P3-10-07: T5 Is a New Molecular Predictor of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Breast Cancer (2010) (0)
[Transposition and myocutaneous island flaps in primary or secondary locoregional surgical therapy of breast cancer]. (1988) (0)
[Palliative laser therapy in gynecologic oncology]. (1992) (0)
[Blind prophylactic antibiotic administration in premature rupture of fetal membranes]. (1997) (0)
Side Effects and Major Complications of Breast-Conserving Therapy (1989) (0)
Lahystotrain — integration of virtual environments and intelligent training systems for laparoscopy and hysteroscopy (2000) (0)
Correlation of acid ceramidase (AC), a key enzyme of the sphingolipid metabolism, with prognosis in epithelial ovarian cancer. (2011) (0)
[Value of fetal lung maturity assessment in maternal diabetes]. (1999) (0)
[Breast saving operation and adjuvant therapy of breast cancer. Report of the National Institute of Health (NIH) Consensus Development Conference, Washington D.C. 18-21 June 1990]. (1990) (0)
Expression of Cytokeratin 8 (CK8) in Human Endometrium and Endometriosis (2008) (0)
Comprar Management of Breast Diseases | Kaufmann, Manfred | 9783540697428 | Springer (2009) (0)
Comparison of Prognostic Signatures in Node-Negative Tamoxifen-Treated Breast Cancer Patients. (2009) (0)
Validation of Plexin B1 as a prognostic and predicitive marker in gene expression datasets of 1363 breast cancer patients (2008) (0)
More power than knowledge? - The molecular therapy of breast cancer: Prospects of translational medicine in Germany (2008) (0)
[Comparison of binding patterns of established and new monoclonal antibodies, of antisera and lectins with impulse cytophotometric and morphometric parameters and the hormone receptor status of breast cancer]. (1985) (0)
Clinical risk factors for complications associated with ECG-guided portacath use in breast cancer patients. (2010) (0)
Mitoxantrone/prednimustine combination therapy in advanced breast cancer—A phase II study (1986) (0)
Author reply (0)
[Sensitivity tests of human malignant tumors to cytostatic drugs]. (1971) (0)
12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set) (2012) (0)
[Immunodiagnostic aspects of breast cancer. The phenomenon of leukocyte adherence inhibition]. (1978) (0)
308 Influence of time and therapy on the receptor status in multiple biopsies of breast cancer patients (1983) (0)
Short-term assay (radiolabeled DNA-precursor uptake method) in gynecologic malignancies. Methodology and results. (1994) (0)
Downregulation of PLK1 elevates chemosensitivity of various breast cancer cell lines in vitro and in vivo. (2006) (0)
Breast Cancer, inflammation and proliferation (2008) (0)
[Initial experiences with laparoscopic intraoperative ultrasound]. (1995) (0)
The molecular classification of breast cancer according to the stem-cell model provides important informations for systemic adjuvant treatment decision (2008) (0)
Title Page / Contents / Foreword (1995) (0)
11. Dosage adjustment, maximum total dosage (1989) (0)
Abstract P5-10-09: Comparison of the (Non-)Hematological Toxicity and Compliance of Different Anthracycline Containing Regimen with the Standard AC/EC in Elderly Patients with Primary Breast Cancer (2010) (0)
Removal of a broken intrauterine curette point (2001) (0)
Report on the 30th Annual San Antonio Breast Cancer Symposium held from December 13 - 16, 2007 (2008) (0)
Contribution of tumor-associated lymphocytes to a niche for "stem cell-like" breast cancer cells (2008) (0)
5. Modes of chemotherapy (1989) (0)
DNA-ploidy (DI) and S-phase fraction (SPF) as prognostic and predictive factors in endometrial cancer (1993) (0)
Adjuvant therapy for breast cancer (1991) (0)
TRANSPORT OF A SELECTED SUBSTANCE INTO CELLS (2017) (0)
Correspondence (letter to the editor): imaging is not sufficient. (2009) (0)
00030 INFORMATION NEEDS AND PREFERENCES OF WOMEN WITH ADJUVANT AND METASTATIC BREAST CANCER (BC): RESULTS OF A SURVEY IN GERMANY (2005) (0)
Detection of MDR-glycoprotein GP170 in primary epithelial ovarian (OC) and node-negative breast (BC) cancer: 139 (1994) (0)
14. Publications recommended for use by patients (1989) (0)
Indications for the sentinel node: multicentric, size of tumor, prior surgery (2008) (0)
S Phase Fractions and DNA Ploidy as Prognostic Factors in Breast Cancer (1989) (0)
Contents of Forthcoming Issues · Themenvorschau (2008) (0)
[The bipolar needle electrode in surgical laparoscopy. Initial technical experimental and clinical results]. (1994) (0)
[Intra-arterial chemotherapy in locally advanced breast carcinomas]. (1991) (0)
Value of Electrical Impedance Scanning ( EIS ) in the Evaluation of BI-RADS TM III (2004) (0)
[A rapid test procedure for the detection of B streptococci in the perinatal period]. (1990) (0)
Kongressberichte – Congress Reports (1994) (0)
Expression of O6-methylguanine-DNA methyltransferase in human tumors (1996) (0)
Use of microarray analysis of differentially expressed genes in luminal B subtype of breast cancers to evaluate NHERF1 as a marker of endocrine resistance. (2009) (0)
[Laser in gynecology. Palliative laser treatment in genital and breast cancers]. (1995) (0)
Update on endocrine approaches in the treatment and prevention of breast cancer (1998) (0)
Updated survival analyses from the ZEBRA study: goserelin vs CMF in premenopausal women with node-positive breast cancer (2003) (0)
Downregulation of cyclin B1 inhibits proliferation of breast cancer cells (2005) (0)
Information needs and preferences of women with adjuvant and metastatic breast cancer (BC): Results of a survey in Germany (2005) (0)
Prognostic and predictive factors in breast cancer (1989) (0)
Immunocytochemical Detection of Estrogen Receptors in Fine-Needle Aspirates of Breast Cancer (1988) (0)
The ‘ZEBRA’ study: An open randomised trial of ‘zoladex’ vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less (1998) (0)
[Diagnosis and therapy of breast cancer--meeting highlights ASCO 2005]. (2005) (0)
Correlation of Thymidine Phosphorylase Expression and Lymphocyte Infiltration Detected by Microarray Analysis of Breast Cancer. (2009) (0)
VEGF-A and COX-2 expression correlate with platinum resistance in ovarian cancers. (2006) (0)
Preoperative (Neoadjuvant) Systemic Therapy (2010) (0)
ER-β Promotrmethylierung korreliert mit der Entstehung des invasiven Mammakarzinoms (2005) (0)
[Successful pregnancy after kidney transplantation and cyclosporin A]. (1986) (0)
[Adjuvant chemotherapy in breast cancer: present status]. (1984) (0)
Neoadjuvant breast cancer therapy: the German experience (2008) (0)
[Sensitivity tests of malignant tumours against cytostatic agents in vitro and in vivo/studies on the mouse sarcoma 180 (author's transl)]. (1975) (0)
Leukocyte Adherence in Patients Clinically Suspected Breast Cancer Using a Panel of Breast Carcinoma Extracts Inhibition (LAI) Tests of Having (1979) (0)
Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) – a German health economic analysis. (2009) (0)
Myoma enucleation during cesarean section: elective procedure or incalculable risk? (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Manfred Kaufmann?

Manfred Kaufmann is affiliated with the following schools: